Früher antiexsudativer Effekt – OCT-Monitoring nach intravitrealer Bevacizumab-Applikation-Reference-Cited by-同舟云学术

Früher antiexsudativer Effekt – OCT-Monitoring nach intravitrealer Bevacizumab-Applikation

Published:2006-06 Issue:6 Volume:103 Page:476-483
ISSN:0941-293X
Container-title:Der Ophthalmologe
language:de
Short-container-title:Ophthalmologe

Author:

Völcker M.,Peters S.,Inhoffen W.,Ziemssen F.

Publisher

Springer Science and Business Media LLC

Subject

Ophthalmology

Link

http://link.springer.com/content/pdf/10.1007/s00347-006-1356-1.pdf

Reference49 articles.

1. Aiello LP, Bursell SE, Clermont A et al. (1997) Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. Diabetes 46: 1473–1480

2. Antonetti DA, Barber AJ, Hollinger LA et al. (1999) Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1. A potential mechanism for vascular permeability in diabetic retinopathy and tumors. J Biol Chem 274: 23463–23467

3. Avery RL, Pieramici DJ, Rabena MD et al. (2006) Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 113: 363–372

4. Bates DO (1998) The chronic effect of vascular endothelial growth factor on individually perfused frog mesenteric microvessels. J Physiol 513 (Pt 1): 225–233

5. Bates DO, Curry FE (1996) Vascular endothelial growth factor increases hydraulic conductivity of isolated perfused microvessels. Am J Physiol 271(6 Pt 2): H2520–H2528

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Photodynamic therapy in combination with ranibizumab versus ranibizumab monotherapy for wet age-related macular degeneration: A systematic review and meta-analysis;Photodiagnosis and Photodynamic Therapy;2018-06

2. Treatment of neovascular age-related macular degeneration with a variable ranibizumab dosing regimen and one-time reduced-fluence photodynamic therapy: the TORPEDO trial at 2 years;Graefe's Archive for Clinical and Experimental Ophthalmology;2010-03-04

3. EFFICACY OF 1.25 MG VERSUS 2.5 MG INTRAVITREAL BEVACIZUMAB FOR DIABETIC MACULAR EDEMA;Retina;2009-03

4. VERTEPORFIN COMBINATION REGIMENS IN THE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION;Retina;2009-02

5. Chancen und Risiken der Anti-VEGF-Therapie;Klinische Monatsblätter für Augenheilkunde;2008-09